|Description||Bevenopran is a peripherally selective μ- and δ-opioid receptor antagonist. It is used for the treatment of chronic opioid-induced constipation. It was developed by Cubist Pharmaceuticals and was in clinical phase 3 trial, but now it is terminated.|
|Solubility||Soluble in DMSO, not in water|
|Application||Bevenopran is used for the treatment of chronic opioid-induced constipation.|
|Quality Standard||In-house standard|
|Boiling Point||575.0±50.0 °C | Condition: Press: 760 Torr|
|Density||1.204±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||Bevenopran was developed by Cubist Pharmaceuticals and was in clinical phase 3 trial, but now it is terminated.|
Naloxone HCl is an opioid inverse agonist drug used to counter the effects of opiate overdose.
LY 106737 is phenylpiperidine opioid receptor antagonist, but no detailed information has been published yet.
The racemate form of TRV130 which is an oxaspiro compound that has been found to be a μ-opioid receptor G protein ligand and could be used in pain therapy.
6 α-naloxol, a human metabolite of naloxone, is an opioid antagonist.
Difelikefalin is an analgesic opioid peptide acting as a peripherally specific, highly selective agonist of the κ-opioid receptor (KOR). It acts as an analgesic...
Endomorphin 2, an andogenous peptide, has high affinity and specificity for the μ-opioid receptor and displays reasonable affinities for kappa3 binding sites, w...
PD-117302, a new nonpeptide opioid compound, is a selective kappa-opioid agonist. It has been evaluated in vivo for antinociceptive activity and other effects c...
LY2795050, a κ-opioid Receptor antagonist, has been found to be effective in imaging KOR behaving as a PET tracer. IC50: 0.72 nM and 25.8 nM for κ-opioid Recept...
Trimebutine is an opioid receptor agonist used as spasmolytic agent abdominal pain.
LY-190388 is an μ receptor agonist. It is a penicillamine-containing enkephalin analog and has analgesia effect.
CP866087 is a selective mu-opioid receptor antagonist.
LY-2456302, also called as CERC-501, is a potent, highly selective and centrally-penetrant kappa opioid receptor antagonist(Ki= 0.807 nM)with favorable pharmaco...
The monohydrate salt form of Alvimopan could be commonly used in postoperative recovery of gastrointestinal for acting as a mu-opioid receptor (PAM-OR) antagoni...
TRV130 is an opioid drug that is under ｅvaluation in human clinical trials for the treatment of acute severe pain. It is a functionally selective μ-opioid recep...
Cebranopadol is a novel first in class compounds with potent agonist activity on opioid receptor like -1(ORL-1) and the well established mu opioid receptor. lt ...
Loperamide HCl is an opioid-receptor agonist with an ED50 of 0.15 mg/kg.
TRV130 is an oxaspiro compound that has been found to be a μ-opioid receptor G protein ligand and could be used in pain therapy. IC50: 8.1 (pEC50. G protein ass...
BAN ORL 24
BAN ORL 24, a spiro-isobenzofuran compound, has been found to be a NOP receptor antagonist and could be used to restrain the reduction of locomotor motions with...
JNJ-20788560 is a delta opioid agonist analgesics. No recent reports of development identified for preclinical development in Inflammatory-pain in USA.
Alvimopan is a novel, oral, peripherally acting antagonist of the mu opioid receptor, which can help gastrointestinal recovery after surgery. Phase III IC50: Mu...